Pharmaceutical - Respiratory and Pulmonary, Oncology


Popular Filters

2014 “drugs to watch” as potential blockbusters

2014 “drugs to watch” as potential blockbusters


The Thomson Reuters Intellectual Property & Science business has released its annual forecast of the…

AfrezzaAnoro ElliptaAnti-viralsCyramzaEli LillyGilead SciencesGlaxoSmithKlineidelalisibMannKindMarkets & MarketingOncologyPharmaceuticalRespiratory and PulmonarySovaldi

MedImmune joins research collaboration with the University of California

MedImmune joins research collaboration with the University of California


MedImmune, the global biologics research and development arm of Anglo-Swedish drug major AstraZeneca,…

Antibiotics and Infectious diseasesCardio-vascularInflammatory diseasesMedImmuneMetabolicsNeurologicalOncologyPharmaceuticalResearchRespiratory and PulmonaryUSA

Return to growth: AstraZeneca’s CEO Pascal Soriot says 2013 was year of “momentum” for the company

Return to growth: AstraZeneca’s CEO Pascal Soriot says 2013 was year of “momentum” for the company


‘Momentum’ is the word which best describes 2013, according to AstraZeneca’s chief executive Pascal…

AstraZenecaBrilintaCardio-vascularCrestorDiabetesExenatide InjectionFinancialInterviewsNexiumOncologyPharmaceuticalRespiratory and PulmonarySymbicortUK

Bayer CEO calls for greater appreciation of innovation

Bayer CEO calls for greater appreciation of innovation


Advances in cancer therapy are expected in the next years, thanks in particular to treatment using antibody-drug…

BayerNephrology and HepatologyOncologyPharmaceuticalResearchRespiratory and Pulmonary

FDA approves Bayer’s Adempas; firm accelerates drug candidates

FDA approves Bayer’s Adempas; firm accelerates drug candidates


The US Food and Drug Administration late yesterday approved Adempas (riociguat), developed by German…

AdempasBayerCardio-vascularcopanlisibfinerenoneNorth AmericaOncologyPharmaceuticalRegulationResearchRespiratory and PulmonaryWomen's Health

IN FOCUS: Boehringer Ingelheim presents its

IN FOCUS: Boehringer Ingelheim presents its "long and healthy" R&D pipeline


German family-owned drug major Boehringer Ingelheim presented its major pipeline developments at an R&D…

afatinibBoehringer IngelheimDiabetesEuropeInterviewslinagliptinnintedanibOncologyPharmaceuticalResearchRespiratory and Pulmonaryvolasertib

Research briefs: Lilly's Forteo; Genmab/GSK's Arzerra; AstraZeneca's Symbicort


US drug major Eli Lilly (NYSE: LLY) has reported new data demonstrating that Forteo (teriparatide) significantly…

Anti-Arthritics/RheumaticsArzerraAstraZenecaEli LillyForteoGenmabGlaxoSmithKlineOncologyPharmaceuticalResearchRespiratory and PulmonarySymbicort

News briefs from Sanofi, Bayer, GlaxoSmithKline and Novartis


French drug major Sanofi (Euronext: SAN) has entered into a binding agreement to acquire the animal health…

BayerDosch PharmaceuticalsExjadeFlonaseGlaxoSmithKlineLegalMergers & AcquisitionsMerialNovartisOncologyPharmaceuticalregorafenibRegulationRespiratory and PulmonarySanofi

Boehringer Ingelheim highlights robust respiratory R&D pipeline; announces investment


At its 3rd International Research & Development press conference, family-owned German drug major Boehringer…

afatinibBoehringer IngelheimnintedanibolodaterolOncologyPharmaceuticalProductionResearchRespimatRespiratory and Pulmonary

EU approval for Janssen-Cilag's Dacogen and Novartis/Vectura's Seebri Breezhealer


The European Commission on Friday approved the marketing authorization for Janssen-Cilag's (a unit of…

Astex PharmaceuticalsDacogenEuropeJanssen-CilagJohnson & JohnsonNovartisOncologyPharmaceuticalRegulationRespiratory and PulmonarySeebri BreezhalerVectura

Europe's CHMP issues positive opinions on aclidinium, Fycompa, Inlyta and NovoThirteen


At its regular monthly meeting last week, the European Medicines Agency's Committee for Medicinal Products…

AlmirallBretaris GenuairEisaiEklira GenuairEuropeFycompaInlytaNeurologicalNovo NordiskNovoThirteenOncologyPfizerPharmaceuticalRespiratory and Pulmonary

Ablynx extends Nanobody deal with Boehringer


Belgian drug developer Ablynx (Euronext Brussels: ABLX) yesterday announced a two-year extension of the…

AblynxBiotechnologyBoehringer IngelheimImmunologicalsLicensingOncologyPharmaceuticalRespiratory and Pulmonary

Caelyx and Ceplene manufacturing should be moved, says EMA


The European Medicines Agency has recommended that the manufacturing processes for the anticancer medicines…

Boehringer IngelheimCaelyxCepleneEpiCeptJanssen-CilagJohnson & JohnsonOncologyPharmaceuticalRegulationRespiratory and Pulmonary

B-MS ties knot with Duke University on R&D


Bristol-Myers Squibb has forged a partnership with Duke University in the USA that will see the academic…

Bristol-Myers SquibbCardio-vascularGeneralHomeLysophosphatidic acid 1 (LPA1)MetabolicsOncologyPfizerPharmaceuticalRespiratory and PulmonarySanofi

NICE publishes final technology appraisal guidance for four conditions


The UK’s drugs watch dog the National Institute for Health and Clinical Excellence (NICE) has today…

AvastinCardio-vascularDaxasEliquisErbituxEuropeOncologyPharmaceuticalPricingRegulationRespiratory and PulmonaryRituxanVectibix

UK NICE negative on Sanofi’s Jevtana and GSK’s Benlysta but positive on ALK-Abello’s Pharmalgen


UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) this morning issued…

Alk-AbelloBenlystaEuropeGlaxoSmithKlineJevtanaOncologyPharmaceuticalPharmalgenPricingRare diseasesRegulationRespiratory and PulmonarySanofi

Chugai gets rights to develop Roche’s MetMab and lebrikizumab in Japan


Japanese drugmaker Chugai Pharmaceutical (TYO: 4519)l has entered into license agreements with its majority…

Asia-PacificChugai PharmaceuticallebrikizumabLicensingMetMAbOncologyPharmaceuticalRespiratory and PulmonaryRoche

Back to top